Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

NasdaqGS:ROIV
NasdaqGS:ROIVBiotechs

A Look At Roivant Sciences (ROIV) Valuation After Brepocitinib Timeline Acceleration And Profitability Outlook Shift

Roivant Sciences (ROIV) is back in focus after recent analyst commentary related to its lead drug candidate, brepocitinib. The company now has accelerated timelines along with updated expectations around costs and future profitability. See our latest analysis for Roivant Sciences. Roivant’s shares have been volatile around the recent brepocitinib updates, with the latest share price at US$21.30, a 90 day share price return of 32.88% and a 1 year total shareholder return of 84.90%. This...